Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Debt (2016 - 2025)

Sanofi's Non-Current Debt history spans 7 years, with the latest figure at $16.6 billion for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 31.63% year-over-year to $16.6 billion; the TTM value through Dec 2025 reached $16.6 billion, up 31.63%, while the annual FY2025 figure was $16.1 billion, 26.14% up from the prior year.
  • Non-Current Debt for Q4 2025 was $16.6 billion at Sanofi, up from $12.6 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $19.6 billion in Q4 2021 and bottomed at $12.6 billion in Q4 2024.
  • The 5-year median for Non-Current Debt is $15.4 billion (2023), against an average of $15.9 billion.
  • The largest annual shift saw Non-Current Debt fell 22.62% in 2022 before it surged 31.63% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $19.6 billion in 2021, then dropped by 22.62% to $15.2 billion in 2022, then increased by 1.84% to $15.4 billion in 2023, then decreased by 18.38% to $12.6 billion in 2024, then soared by 31.63% to $16.6 billion in 2025.
  • Per Business Quant, the three most recent readings for SNY's Non-Current Debt are $16.6 billion (Q4 2025), $12.6 billion (Q4 2024), and $15.4 billion (Q4 2023).